Latest news

• Amgen buys Danish partner Nuevolution for $167m

  The company is starting to face biosimilar competition for white blood cell stimulator Neulasta (pegfilgrastim) as well as generic encroachment on Sensipar (cinacalcet) for secondary hyperparathyroidism, which together accounted for around

• Amgen CEO says Aimovig is “one of most successful launches”

  Overall, Amgen posted a 2% rise in revenues to $5.78bn in the quarter, despite pressure on older drugs like while blood cell booster Neulasta (pegfilgrastim) which showed the first signs

• Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

  The three biosimilars are: Mylan’s Hulio (adalimumab), a version of AbbVie’s big-selling Humira for the treatment of certain inflammatory and autoimmune disorders; and Accord Healthcare’s Pelgraz (pegfilgrastim) ... and ERA Consulting’s Udenyca

• Novartis doubles down on biosimilars with Biocon alliance

  drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.

• Biocon backs away from biosimilar filings in Europe

  white cell booster Neulasta (pegfilgrastim) at the request of the EMA.